Status:
COMPLETED
Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)
Lead Sponsor:
MeiraGTx UK II Ltd
Conditions:
Leber Congenital Amaurosis
Eligibility:
All Genders
3+ years
Phase:
PHASE1
PHASE2
Brief Summary
A clinical trial of AAV2/5 vector for patients with Defects in RPE65
Detailed Description
A dose escalation and dose expansion (Phase I/II) trial of adults and children with retinal dystrophy associated with defects in RPE65. ATIMP will be administered to one eye only in a single sub-retin...
Eligibility Criteria
Inclusion
- Key
- Aged 3 years or older
- Early-onset severe retinal dystrophy consistent with RPE65 deficiency
- Key
Exclusion
- Females who are pregnant or breastfeeding
- Have participated in another research study involving an investigational therapy for ocular disease within the last 6 months.
Key Trial Info
Start Date :
April 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT02781480
Start Date
April 1 2016
End Date
December 1 2018
Last Update
July 12 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Kellogg Eye Centre, University of Michigan
Ann Arbor, Michigan, United States, 48105
2
Moorfields Eye Hospital NHS Foundation Trust
London, United Kingdom, EC1V 2PD